{
    "id": 102,
    "premise": "none",
    "hypothesis": "Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L",
    "label": "entailment",
    "explanation": "Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L",
        "history explanation": [
            "0 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
            "1 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
            "2 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
            "3 iteration: Lapatinib and neratinib being effective against tumors with mutations in the kinase domain implies that they are effective in breast cancer patients.\nThe efficacy of Lapatinib and neratinib against tumors with mutations in the kinase domain leads to their effectiveness in breast cancer patients.",
            "4 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients implies a potential benefit for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients can lead to a positive outcome for the patient in terms of accessing suitable treatments.",
            "5 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients implies a potential benefit for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients can lead to a positive outcome for the patient in terms of accessing suitable treatments.",
            "6 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments.",
            "7 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments.",
            "8 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments.",
            "9 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options.\nThe effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments.",
            "10 iteration: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to specific benefits for the patient in terms of treatment options, including the potential to access clinical trials for specific treatments.\nThe positive outcomes for the patient resulting from the effectiveness of Lapatinib and Neratinib in breast cancer patients include the ability to access suitable treatments tailored to the patient's condition."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_102_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Bind :: \"event \u21d2 bool\"\\n  Drug :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 entity\"\\n  EfficacyAgainst :: \"event \u21d2 bool\"\\n  TumorsWithMutation :: \"event \u21d2 entity \u21d2 bool\"\\n  Lapatinib :: \"entity\"\\n  Neratinib :: \"entity\"\\n  \\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y e. (Bind e \u2227 Drug e Lapatinib \u2227 To e (HER2KinaseDomain x)) \u2228 (Bind e \u2227 Drug e Neratinib \u2227 To e (HER2KinaseDomain y)) \u2227 EfficacyAgainst e \u2227 TumorsWithMutation e x\"\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  OvercomeResistance :: \"event \u21d2 bool\"\\n  EffectiveIn :: \"event \u21d2 entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity\"\\n  \\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x (HER2KinaseDomain y) \u2227 OvercomeResistance e \u2227 EffectiveIn e BreastCancerPatients\"\\n\\nconsts\\n  ERBB2V777L :: \"entity \u21d2 bool\"\\n  ClinicalTrial :: \"entity \u21d2 entity\"\\n  BreastCarcinoma :: \"entity \u21d2 bool\"\\n  Open :: \"entity \u21d2 bool\"\\n  Closed :: \"entity \u21d2 bool\"\\n  NumberOfTrials :: \"entity \u21d2 nat\"\\n  \\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x. ERBB2V777L x \u2227 InclusionCriterionIn x (ClinicalTrial y) \u2227 BreastCarcinoma y \u2227 Open y \u2227 \u00acClosed y \u2227 NumberOfTrials x (4::nat)\"\\n\\nconsts\\n  Trial :: \"entity \u21d2 bool\"\\n  Contains :: \"entity \u21d2 entity \u21d2 bool\"\\n  InclusionCriteria :: \"entity \u21d2 entity\"\\n  Phase1Phase2 :: \"entity \u21d2 bool\"\\n  Phase2 :: \"entity \u21d2 bool\"\\n  \\n(* Explanation 4: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z. Trial x \u2227 Contains x ERBB2V777L \u2227 Contains x BreastCarcinoma \u2227 InclusionCriteria x y \u2227 (Phase1Phase2 y \u2227 Open y \u2227 NumberOfTrials y (1::nat)) \u2228 (Phase2 z \u2227 Open z \u2227 NumberOfTrials z (3::nat))\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x e. Patient x \u2227 (BenefitFrom e \u2227 Treatment e Neratinib) \u2228 (BenefitFrom e \u2227 Treatment e Lapatinib) \u2228 (Access e \u2227 ClinicalTrial e \u2227 ForTreatmentOf e ERBB2V777L)\"\\nproof -\\n  (* From the premise, we know the patient x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* We have the following implications from the explanations and logical relations:\\n     - Implies(A and B, C): Lapatinib and neratinib bind to the HER2 kinase domain implies an irreversible inhibitor targeted to the HER2 kinase domain.\\n     - Implies(C, D and E): An irreversible inhibitor targeted to the HER2 kinase domain implies effective in breast cancer patients.\\n     - Implies(F, J): ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma implies trials containing ERBB2 V777L and breast carcinoma as inclusion criteria.\\n     - Implies(G, N): 4 clinical trials for breast carcinoma implies 3 open phase 2 trials.\\n     - Implies(J, N): Trials containing ERBB2 V777L and breast carcinoma as inclusion criteria implies 3 open phase 2 trials.\\n     - Implies(N, M): 3 open phase 2 trials implies 3 phase 2 trials.\\n  *)\\n  (* We can use these implications to infer the necessary conditions for the hypothesis. *)\\n  have \"EffectiveIn e BreastCancerPatients\" if \"An irreversible x \u2227 TargetedTo x (HER2KinaseDomain y) \u2227 OvercomeResistance e\" for x y e <ATP>\\n  have \"BenefitFrom e \u2227 Treatment e Neratinib\" if \"(Bind e \u2227 Drug e Neratinib \u2227 To e (HER2KinaseDomain y)) \u2227 EfficacyAgainst e \u2227 TumorsWithMutation e x\" for x y e <ATP>\\n  have \"BenefitFrom e \u2227 Treatment e Lapatinib\" if \"(Bind e \u2227 Drug e Lapatinib \u2227 To e (HER2KinaseDomain y)) \u2227 EfficacyAgainst e \u2227 TumorsWithMutation e x\" for x y e <ATP>\\n  have \"Access e \u2227 ClinicalTrial e \u2227 ForTreatmentOf e ERBB2V777L\" if \"ERBB2V777L x \u2227 InclusionCriterionIn x (ClinicalTrial y) \u2227 BreastCarcinoma y \u2227 Open y \u2227 \u00acClosed y \u2227 NumberOfTrials x 4\" for x y <ATP>\\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain\\nB: expected efficacy against tumors with mutations in the kinase domain\\nC: an irreversible inhibitor targeted to the HER2 kinase domain\\nD: may overcome treatment resistance\\nE: effective in breast cancer patients\\nF: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma\\nG: 4 clinical trials for breast carcinoma\\nH: 4 open clinical trials for breast carcinoma\\nI: 0 closed clinical trials for breast carcinoma\\nJ: trials containing ERBB2 V777L and breast carcinoma as inclusion criteria\\nK: 1 phase 1/phase 2 trial\\nL: 1 open phase 1/phase 2 trial\\nM: 3 phase 2 trials\\nN: 3 open phase 2 trials\\n\\nLogical Relations:\\nImplies(A and B, C)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(C, D and E)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, effective in breast cancer patients)\\n--------\\nEquivalent(F, J)\\nEquivalent(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nEquivalent(G, 4)\\n4 clinical trials for breast carcinoma\\n--------\\nEquivalent(H, 4)\\n4 open clinical trials for breast carcinoma\\n--------\\nEquivalent(I, 0)\\nNot(0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(J, K and M)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 3 phase 2 trials)\\n--------\\nEquivalent(K, 1)\\n1 phase 1/phase 2 trial\\n--------\\nEquivalent(L, 1)\\n1 open phase 1/phase 2 trial\\n--------\\nEquivalent(M, 3)\\n3 phase 2 trials\\n--------\\nEquivalent(N, 3)\\n3 open phase 2 trials\\n--------\\n\\nDerived Implications:\\nImplies(Not(F), K)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), G)\\nImplies(Not(3 phase 2 trials), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(E, L)\\nImplies(effective in breast cancer patients, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(H, N)\\nImplies(4 open clinical trials for breast carcinoma, 3 open phase 2 trials)\\n--------\\nImplies(Not(K), Not(E))\\nImplies(Not(1 phase 1/phase 2 trial), Not(effective in breast cancer patients))\\n--------\\nImplies(L, K)\\nImplies(1 open phase 1/phase 2 trial, 1 phase 1/phase 2 trial)\\n--------\\nImplies(I, L)\\nImplies(0 closed clinical trials for breast carcinoma, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(N), B)\\nImplies(Not(3 open phase 2 trials), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(G), F)\\nImplies(Not(4 clinical trials for breast carcinoma), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(E, Not(I))\\nImplies(effective in breast cancer patients, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(M, K)\\nImplies(3 phase 2 trials, 1 phase 1/phase 2 trial)\\n--------\\nImplies(F, L)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), Not(N))\\nImplies(Not(1 phase 1/phase 2 trial), Not(3 open phase 2 trials))\\n--------\\nImplies(Not(M), Not(F))\\nImplies(Not(3 phase 2 trials), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), M)\\nImplies(Not(3 open phase 2 trials), 3 phase 2 trials)\\n--------\\nImplies(F, Not(I))\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), C)\\nImplies(Not(3 open phase 2 trials), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(N), Not(L))\\nImplies(Not(3 open phase 2 trials), Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(Not(J), M)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 3 phase 2 trials)\\n--------\\nImplies(B, L)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), K)\\nImplies(Not(3 phase 2 trials), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(L), Not(B))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(N, H)\\nImplies(3 open phase 2 trials, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(K, G)\\nImplies(1 phase 1/phase 2 trial, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(B, Not(I))\\nImplies(expected efficacy against tumors with mutations in the kinase domain, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(M, H)\\nImplies(3 phase 2 trials, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(4 open clinical trials for breast carcinoma), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(N), Not(M))\\nImplies(Not(3 open phase 2 trials), Not(3 phase 2 trials))\\n--------\\nImplies(K, M)\\nImplies(1 phase 1/phase 2 trial, 3 phase 2 trials)\\n--------\\nImplies(Not(L), Not(G))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), B)\\nImplies(Not(4 clinical trials for breast carcinoma), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(N), E)\\nImplies(Not(3 open phase 2 trials), effective in breast cancer patients)\\n--------\\nImplies(Not(N), Not(J))\\nImplies(Not(3 open phase 2 trials), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(H), C)\\nImplies(Not(4 open clinical trials for breast carcinoma), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(H), M)\\nImplies(Not(4 open clinical trials for breast carcinoma), 3 phase 2 trials)\\n--------\\nImplies(Not(K), G)\\nImplies(Not(1 phase 1/phase 2 trial), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(C, M)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 3 phase 2 trials)\\n--------\\nImplies(Not(L), Not(C))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(B), N)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 3 open phase 2 trials)\\n--------\\nImplies(H, L)\\nImplies(4 open clinical trials for breast carcinoma, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), C)\\nImplies(Not(4 clinical trials for breast carcinoma), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(G), M)\\nImplies(Not(4 clinical trials for breast carcinoma), 3 phase 2 trials)\\n--------\\nImplies(H, Not(I))\\nImplies(4 open clinical trials for breast carcinoma, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(H), Not(M))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(3 phase 2 trials))\\n--------\\nImplies(Not(G), Not(L))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(Not(H), K)\\nImplies(Not(4 open clinical trials for breast carcinoma), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), Not(F))\\nImplies(Not(1 phase 1/phase 2 trial), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(N), H)\\nImplies(Not(3 open phase 2 trials), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(4 open clinical trials for breast carcinoma), effective in breast cancer patients)\\n--------\\nImplies(Not(F), N)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 3 open phase 2 trials)\\n--------\\nImplies(Not(M), Not(K))\\nImplies(Not(3 phase 2 trials), Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(L, N)\\nImplies(1 open phase 1/phase 2 trial, 3 open phase 2 trials)\\n--------\\nImplies(Not(G), Not(H))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(Not(L), I)\\nImplies(Not(1 open phase 1/phase 2 trial), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(B))\\nImplies(0 closed clinical trials for breast carcinoma, Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(G), Not(M))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(3 phase 2 trials))\\n--------\\nImplies(M, N)\\nImplies(3 phase 2 trials, 3 open phase 2 trials)\\n--------\\nImplies(K, H)\\nImplies(1 phase 1/phase 2 trial, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(4 clinical trials for breast carcinoma), effective in breast cancer patients)\\n--------\\nImplies(Not(G), Not(J))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(I, Not(G))\\nImplies(0 closed clinical trials for breast carcinoma, Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(C, H)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), F)\\nImplies(Not(1 open phase 1/phase 2 trial), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), N)\\nImplies(Not(3 phase 2 trials), 3 open phase 2 trials)\\n--------\\nImplies(N, G)\\nImplies(3 open phase 2 trials, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(J, F)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(C))\\nImplies(0 closed clinical trials for breast carcinoma, Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(G), H)\\nImplies(Not(4 clinical trials for breast carcinoma), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), J)\\nImplies(Not(3 phase 2 trials), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(B), L)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(B), Not(I))\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(N, K)\\nImplies(3 open phase 2 trials, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(F), L)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(K, N)\\nImplies(1 phase 1/phase 2 trial, 3 open phase 2 trials)\\n--------\\nImplies(N, L)\\nImplies(3 open phase 2 trials, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), Not(N))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(3 open phase 2 trials))\\n--------\\nImplies(Not(L), B)\\nImplies(Not(1 open phase 1/phase 2 trial), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(F), Not(I))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(M, L)\\nImplies(3 phase 2 trials, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), N)\\nImplies(Not(4 open clinical trials for breast carcinoma), 3 open phase 2 trials)\\n--------\\nImplies(L, Not(I))\\nImplies(1 open phase 1/phase 2 trial, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(J), G)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(N), G)\\nImplies(Not(3 open phase 2 trials), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(M, Not(I))\\nImplies(3 phase 2 trials, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(K), N)\\nImplies(Not(1 phase 1/phase 2 trial), 3 open phase 2 trials)\\n--------\\nImplies(Not(H), J)\\nImplies(Not(4 open clinical trials for breast carcinoma), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(I, F)\\nImplies(0 closed clinical trials for breast carcinoma, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), C)\\nImplies(Not(1 open phase 1/phase 2 trial), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(L), M)\\nImplies(Not(1 open phase 1/phase 2 trial), 3 phase 2 trials)\\n--------\\nImplies(Not(M), L)\\nImplies(Not(3 phase 2 trials), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(3 open phase 2 trials), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(M), I)\\nImplies(Not(3 phase 2 trials), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(K), J)\\nImplies(Not(1 phase 1/phase 2 trial), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(N), Not(H))\\nImplies(Not(3 open phase 2 trials), Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), K)\\nImplies(Not(3 open phase 2 trials), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), Not(I))\\nImplies(Not(3 phase 2 trials), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(C, G)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(J), K)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(L), Not(J))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(K, L)\\nImplies(1 phase 1/phase 2 trial, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(E), G)\\nImplies(Not(effective in breast cancer patients), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, B)\\nImplies(0 closed clinical trials for breast carcinoma, expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(C, K)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 1 phase 1/phase 2 trial)\\n--------\\nImplies(K, Not(I))\\nImplies(1 phase 1/phase 2 trial, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(H), L)\\nImplies(Not(4 open clinical trials for breast carcinoma), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(E), M)\\nImplies(Not(effective in breast cancer patients), 3 phase 2 trials)\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(H), Not(I))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(C), G)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), K)\\nImplies(Not(4 clinical trials for breast carcinoma), 1 phase 1/phase 2 trial)\\n--------\\nImplies(E, M)\\nImplies(effective in breast cancer patients, 3 phase 2 trials)\\n--------\\nImplies(Not(K), L)\\nImplies(Not(1 phase 1/phase 2 trial), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), I)\\nImplies(Not(1 phase 1/phase 2 trial), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(Not(I), G)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, M)\\nImplies(0 closed clinical trials for breast carcinoma, 3 phase 2 trials)\\n--------\\nImplies(I, Not(L))\\nImplies(0 closed clinical trials for breast carcinoma, Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(I, C)\\nImplies(0 closed clinical trials for breast carcinoma, an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(C), M)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 3 phase 2 trials)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(1 phase 1/phase 2 trial), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(E), K)\\nImplies(Not(effective in breast cancer patients), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(N), Not(K))\\nImplies(Not(3 open phase 2 trials), Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(Not(I), M)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 3 phase 2 trials)\\n--------\\nImplies(Not(N), Not(E))\\nImplies(Not(3 open phase 2 trials), Not(effective in breast cancer patients))\\n--------\\nImplies(F, M)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 3 phase 2 trials)\\n--------\\nImplies(G, M)\\nImplies(4 clinical trials for breast carcinoma, 3 phase 2 trials)\\n--------\\nImplies(Not(C), K)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), Not(B))\\nImplies(Not(3 phase 2 trials), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(I, Not(J))\\nImplies(0 closed clinical trials for breast carcinoma, Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(I), K)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), Not(K))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(Not(J), N)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 3 open phase 2 trials)\\n--------\\nImplies(Not(E), H)\\nImplies(Not(effective in breast cancer patients), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(G, K)\\nImplies(4 clinical trials for breast carcinoma, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), Not(G))\\nImplies(Not(3 phase 2 trials), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), J)\\nImplies(Not(3 open phase 2 trials), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(G), Not(K))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(C), H)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), Not(C))\\nImplies(Not(3 phase 2 trials), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(I), H)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(F, H)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(N, Not(I))\\nImplies(3 open phase 2 trials, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(C, N)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 3 open phase 2 trials)\\n--------\\nImplies(Not(H), Not(B))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(L), G)\\nImplies(Not(1 open phase 1/phase 2 trial), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(J, G)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), Not(N))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(3 open phase 2 trials))\\n--------\\nImplies(G, H)\\nImplies(4 clinical trials for breast carcinoma, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), N)\\nImplies(Not(4 clinical trials for breast carcinoma), 3 open phase 2 trials)\\n--------\\nImplies(Not(K), Not(B))\\nImplies(Not(1 phase 1/phase 2 trial), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(E), N)\\nImplies(Not(effective in breast cancer patients), 3 open phase 2 trials)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(4 clinical trials for breast carcinoma), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(L), Not(F))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), L)\\nImplies(Not(3 open phase 2 trials), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(N), I)\\nImplies(Not(3 open phase 2 trials), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), Not(H))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(Not(J), L)\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), Not(G))\\nImplies(Not(1 phase 1/phase 2 trial), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(Not(L), Not(M))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(3 phase 2 trials))\\n--------\\nImplies(Not(L), K)\\nImplies(Not(1 open phase 1/phase 2 trial), 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(J, K)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(N), Not(I))\\nImplies(Not(3 open phase 2 trials), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(C), N)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 3 open phase 2 trials)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(M), F)\\nImplies(Not(3 phase 2 trials), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), E)\\nImplies(Not(1 open phase 1/phase 2 trial), effective in breast cancer patients)\\n--------\\nImplies(Not(I), N)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 3 open phase 2 trials)\\n--------\\nImplies(Not(K), Not(C))\\nImplies(Not(1 phase 1/phase 2 trial), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(B), M)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 3 phase 2 trials)\\n--------\\nImplies(G, N)\\nImplies(4 clinical trials for breast carcinoma, 3 open phase 2 trials)\\n--------\\nImplies(E, G)\\nImplies(effective in breast cancer patients, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(C, L)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), I)\\nImplies(Not(4 open clinical trials for breast carcinoma), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(I, G)\\nImplies(0 closed clinical trials for breast carcinoma, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), H)\\nImplies(Not(1 open phase 1/phase 2 trial), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(J, H)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(C, Not(I))\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(F, G)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), L)\\nImplies(Not(4 clinical trials for breast carcinoma), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(L, M)\\nImplies(1 open phase 1/phase 2 trial, 3 phase 2 trials)\\n--------\\nImplies(Not(G), I)\\nImplies(Not(4 clinical trials for breast carcinoma), 0 closed clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), B)\\nImplies(Not(3 phase 2 trials), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(G), Not(I))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(E), L)\\nImplies(Not(effective in breast cancer patients), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(4 open clinical trials for breast carcinoma), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(B, G)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(F))\\nImplies(0 closed clinical trials for breast carcinoma, Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(L), Not(K))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(E, K)\\nImplies(effective in breast cancer patients, 1 phase 1/phase 2 trial)\\n--------\\nImplies(I, Not(H))\\nImplies(0 closed clinical trials for breast carcinoma, Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(Not(L), Not(E))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(E), Not(I))\\nImplies(Not(effective in breast cancer patients), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(I, Not(M))\\nImplies(0 closed clinical trials for breast carcinoma, Not(3 phase 2 trials))\\n--------\\nImplies(I, K)\\nImplies(0 closed clinical trials for breast carcinoma, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), F)\\nImplies(Not(1 phase 1/phase 2 trial), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(B, M)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 3 phase 2 trials)\\n--------\\nImplies(I, E)\\nImplies(0 closed clinical trials for breast carcinoma, effective in breast cancer patients)\\n--------\\nImplies(Not(F), Not(J))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(C), L)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), C)\\nImplies(Not(3 phase 2 trials), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(F, K)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(B), H)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(I), L)\\nImplies(Not(0 closed clinical trials for breast carcinoma), 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), Not(L))\\nImplies(Not(3 phase 2 trials), Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(Not(L), Not(N))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(3 open phase 2 trials))\\n--------\\nImplies(Not(C), Not(I))\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(N), Not(B))\\nImplies(Not(3 open phase 2 trials), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(L), N)\\nImplies(Not(1 open phase 1/phase 2 trial), 3 open phase 2 trials)\\n--------\\nImplies(B, K)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 1 phase 1/phase 2 trial)\\n--------\\nImplies(J, N)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 3 open phase 2 trials)\\n--------\\nImplies(G, L)\\nImplies(4 clinical trials for breast carcinoma, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(E, H)\\nImplies(effective in breast cancer patients, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), Not(H))\\nImplies(Not(3 phase 2 trials), Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(H, G)\\nImplies(4 open clinical trials for breast carcinoma, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, H)\\nImplies(0 closed clinical trials for breast carcinoma, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(B, E)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, effective in breast cancer patients)\\n--------\\nImplies(Not(H), B)\\nImplies(Not(4 open clinical trials for breast carcinoma), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(L, H)\\nImplies(1 open phase 1/phase 2 trial, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(G, Not(I))\\nImplies(4 clinical trials for breast carcinoma, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(Not(L), J)\\nImplies(Not(1 open phase 1/phase 2 trial), trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(N), Not(G))\\nImplies(Not(3 open phase 2 trials), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(Not(M), E)\\nImplies(Not(3 phase 2 trials), effective in breast cancer patients)\\n--------\\nImplies(H, M)\\nImplies(4 open clinical trials for breast carcinoma, 3 phase 2 trials)\\n--------\\nImplies(Not(K), B)\\nImplies(Not(1 phase 1/phase 2 trial), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(N), Not(C))\\nImplies(Not(3 open phase 2 trials), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(I, Not(K))\\nImplies(0 closed clinical trials for breast carcinoma, Not(1 phase 1/phase 2 trial))\\n--------\\nImplies(B, H)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(E))\\nImplies(0 closed clinical trials for breast carcinoma, Not(effective in breast cancer patients))\\n--------\\nImplies(Not(H), Not(L))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(H, K)\\nImplies(4 open clinical trials for breast carcinoma, 1 phase 1/phase 2 trial)\\n--------\\nImplies(Not(M), H)\\nImplies(Not(3 phase 2 trials), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(Not(K), C)\\nImplies(Not(1 phase 1/phase 2 trial), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(G), Not(B))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(K), M)\\nImplies(Not(1 phase 1/phase 2 trial), 3 phase 2 trials)\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(Not(K), Not(L))\\nImplies(Not(1 phase 1/phase 2 trial), Not(1 open phase 1/phase 2 trial))\\n--------\\nImplies(I, Not(N))\\nImplies(0 closed clinical trials for breast carcinoma, Not(3 open phase 2 trials))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(effective in breast cancer patients), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(E, N)\\nImplies(effective in breast cancer patients, 3 open phase 2 trials)\\n--------\\nImplies(I, N)\\nImplies(0 closed clinical trials for breast carcinoma, 3 open phase 2 trials)\\n--------\\nImplies(Not(H), Not(J))\\nImplies(Not(4 open clinical trials for breast carcinoma), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(K), Not(H))\\nImplies(Not(1 phase 1/phase 2 trial), Not(4 open clinical trials for breast carcinoma))\\n--------\\nImplies(J, L)\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, 1 open phase 1/phase 2 trial)\\n--------\\nImplies(Not(K), Not(M))\\nImplies(Not(1 phase 1/phase 2 trial), Not(3 phase 2 trials))\\n--------\\nImplies(Not(M), Not(E))\\nImplies(Not(3 phase 2 trials), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(B), G)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(K), E)\\nImplies(Not(1 phase 1/phase 2 trial), effective in breast cancer patients)\\n--------\\nImplies(Not(K), Not(J))\\nImplies(Not(1 phase 1/phase 2 trial), Not(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(L), Not(I))\\nImplies(Not(1 open phase 1/phase 2 trial), Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(F, N)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 3 open phase 2 trials)\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(J, Not(I))\\nImplies(trials containing ERBB2 V777L and breast carcinoma as inclusion criteria, Not(0 closed clinical trials for breast carcinoma))\\n--------\\nImplies(I, J)\\nImplies(0 closed clinical trials for breast carcinoma, trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(N), F)\\nImplies(Not(3 open phase 2 trials), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(M), Not(N))\\nImplies(Not(3 phase 2 trials), Not(3 open phase 2 trials))\\n--------\\nImplies(B, N)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 3 open phase 2 trials)\\n--------\\nImplies(F, J)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials containing ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(F), G)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(L, G)\\nImplies(1 open phase 1/phase 2 trial, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(K), H)\\nImplies(Not(1 phase 1/phase 2 trial), 4 open clinical trials for breast carcinoma)\\n--------\\nImplies(M, G)\\nImplies(3 phase 2 trials, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(F), M)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 3 phase 2 trials)\\n--------\\nImplies(Not(B), K)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 1 phase 1/phase 2 trial)\\n--------\\nImplies(N, M)\\nImplies(3 open phase 2 trials, 3 phase 2 trials)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_102_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Bind :: \"entity \u21d2 entity \u21d2 bool\"\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity\"\\n  Efficacy :: \"entity \u21d2 bool\"\\n  Against :: \"entity \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity\"\\n  WithMutation :: \"entity \u21d2 entity \u21d2 bool\"\\n  \\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  InPatients :: \"event \u21d2 entity \u21d2 bool\"\\n  \\n  ERBB2V777L :: \"entity \u21d2 bool\"\\n  ClinicalTrial :: \"entity \u21d2 bool\"\\n  BreastCarcinoma :: \"entity\"\\n  InclusionCriterion :: \"entity \u21d2 bool\"\\n  InTrial :: \"entity \u21d2 entity \u21d2 bool\"\\n  Open :: \"entity \u21d2 bool\"\\n  Closed :: \"entity \u21d2 bool\"\\n  \\n  Contain :: \"entity \u21d2 entity \u21d2 bool\"\\n  Phase1 :: \"entity \u21d2 bool\"\\n  Phase2 :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z. (Bind x HER2KinaseDomain \u2227 Bind y HER2KinaseDomain \u2227 Lapatinib x \u2227 Neratinib y) \u27f6 (Efficacy z \u2227 Against z Tumors \u2227 WithMutation z HER2KinaseDomain)\"\\n\\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x HER2KinaseDomain \u2227 (Overcome e \u2227 TreatmentResistance e \u2227 Effective e \u2227 InPatients e BreastCancer)\"\\n\\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. ERBB2V777L x \u2227 ClinicalTrial y \u2227 ForDisease y BreastCarcinoma \u2227 InclusionCriterion z \u2227 InTrial z y \u2227 Open y \u2227 Closed y\"\\n\\n(* Explanation 4: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z. (Contain x ERBB2V777L \u2227 Contain x BreastCarcinoma \u2227 InclusionCriterion y \u2227 InTrial y x) \u27f6 ((Phase1 x \u2227 Phase2 x \u2227 Open x) \u2228 (Phase2 x \u2227 Open x))\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x e1 e2 e3. Patient x \u2227 (Benefit e1 \u2227 WithTreatment e1 Neratinib \u2227 ForTreatment e1 ERBB2V777L \u2227 Access e2 \u2227 ClinicalTrial e2 \u2227 ForTreatment e2 ERBB2V777L \u2227 Access e3 \u2227 ClinicalTrial e3 \u2227 ForTreatment e3 ERBB2V777L)\"\\nproof -\\n  (* From the premise, we know that the patient x is seeking treatment. *)\\n  from asm have \"Patient x\" <ATP>\\n  \\n  (* Explanation 1 states that Lapatinib and neratinib bind to the HER2 kinase domain and are expected to have efficacy against tumors with mutations in the kinase domain. *)\\n  (* This implies that expected efficacy against tumors with mutations in the HER2 kinase domain leads to being effective in breast cancer patients. *)\\n  (* Therefore, we can infer that the patient x may benefit from treatment with Neratinib or Lapatinib. *)\\n  then have \"Benefit e1 \u2227 WithTreatment e1 Neratinib \u2227 ForTreatment e1 ERBB2V777L\" <ATP>\\n  \\n  (* Explanation 3 and Explanation 4 provide information about ERBB2 V777L being an inclusion criterion in clinical trials for breast carcinoma. *)\\n  (* This implies that there are clinical trials available for the treatment of ERBB2 V777L. *)\\n  (* Therefore, the patient x may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n  then have \"Access e2 \u2227 ClinicalTrial e2 \u2227 ForTreatment e2 ERBB2V777L\" <ATP>\\n  \\n  (* Similarly, the patient x may have access to another clinical trial for the treatment of ERBB2 V777L. *)\\n  then have \"Access e3 \u2227 ClinicalTrial e3 \u2227 ForTreatment e3 ERBB2V777L\" <ATP>\\n  \\n  (* Combining the above inferences, we have shown that there exist treatments and clinical trials available for the patient x. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain\\nB: expected efficacy against tumours with mutations in the HER2 kinase domain\\nC: an irreversible inhibitor targeted to the HER2 kinase domain\\nD: may overcome treatment resistance\\nE: effective in breast cancer patients\\nF: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma\\nG: 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion\\nH: 4 trials are open\\nI: 0 trials are closed\\nJ: trials contain ERBB2 V777L and breast carcinoma as inclusion criteria\\nK: 1 trial is phase 1/phase 2\\nL: 1 trial is open\\nM: 3 trials are phase 2\\nN: 3 trials are open\\n\\nLogical Relations:\\nImplies(A and B, C)\\nImplies(expected efficacy against tumours with mutations in the HER2 kinase domain, an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(C, D)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, may overcome treatment resistance)\\n--------\\nImplies(D, E)\\nImplies(may overcome treatment resistance, effective in breast cancer patients)\\n--------\\nEquivalent(F, J)\\nEquivalent(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nEquivalent(G, 4)\\n4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion\\n--------\\nImplies(G and I, H)\\nImplies(0 trials are closed, 4 trials are open)\\n--------\\nEquivalent(J, K and L)\\nEquivalent(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 trial is open)\\n--------\\nEquivalent(J, M and N)\\nEquivalent(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 3 trials are open)\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), Not(N))\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), Not(3 trials are open))\\n--------\\nImplies(Not(F), Not(J))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(G), F)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(L), Not(N))\\nImplies(Not(1 trial is open), Not(3 trials are open))\\n--------\\nImplies(N, L)\\nImplies(3 trials are open, 1 trial is open)\\n--------\\nImplies(F, L)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 1 trial is open)\\n--------\\nImplies(J, N)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 3 trials are open)\\n--------\\nImplies(Not(N), G)\\nImplies(Not(3 trials are open), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(effective in breast cancer patients))\\n--------\\nImplies(H, G)\\nImplies(4 trials are open, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(B, E)\\nImplies(expected efficacy against tumours with mutations in the HER2 kinase domain, effective in breast cancer patients)\\n--------\\nImplies(Not(N), Not(L))\\nImplies(Not(3 trials are open), Not(1 trial is open))\\n--------\\nImplies(Not(J), Not(L))\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), Not(1 trial is open))\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(may overcome treatment resistance), Not(expected efficacy against tumours with mutations in the HER2 kinase domain))\\n--------\\nImplies(Not(L), G)\\nImplies(Not(1 trial is open), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(J, G)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), Not(N))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(3 trials are open))\\n--------\\nImplies(Not(D), G)\\nImplies(Not(may overcome treatment resistance), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(3 trials are open), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(H), G)\\nImplies(Not(4 trials are open), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), N)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), 3 trials are open)\\n--------\\nImplies(L, F)\\nImplies(1 trial is open, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), B)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), expected efficacy against tumours with mutations in the HER2 kinase domain)\\n--------\\nImplies(Not(N), Not(J))\\nImplies(Not(3 trials are open), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(C, G)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(N, F)\\nImplies(3 trials are open, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(D, G)\\nImplies(may overcome treatment resistance, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), D)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), may overcome treatment resistance)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(G), Not(B))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(expected efficacy against tumours with mutations in the HER2 kinase domain))\\n--------\\nImplies(Not(L), Not(F))\\nImplies(Not(1 trial is open), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), C)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(effective in breast cancer patients), Not(expected efficacy against tumours with mutations in the HER2 kinase domain))\\n--------\\nImplies(Not(L), Not(J))\\nImplies(Not(1 trial is open), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(G), Not(L))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(1 trial is open))\\n--------\\nImplies(Not(E), G)\\nImplies(Not(effective in breast cancer patients), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(F), Not(N))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(3 trials are open))\\n--------\\nImplies(J, L)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 trial is open)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(may overcome treatment resistance))\\n--------\\nImplies(C, E)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, effective in breast cancer patients)\\n--------\\nImplies(Not(B), G)\\nImplies(Not(expected efficacy against tumours with mutations in the HER2 kinase domain), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(L, N)\\nImplies(1 trial is open, 3 trials are open)\\n--------\\nImplies(F, N)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 3 trials are open)\\n--------\\nImplies(Not(G), Not(H))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(4 trials are open))\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(E, G)\\nImplies(effective in breast cancer patients, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(C), G)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(I, G)\\nImplies(0 trials are closed, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), effective in breast cancer patients)\\n--------\\nImplies(Not(G), Not(J))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(effective in breast cancer patients), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(I), G)\\nImplies(Not(0 trials are closed), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(L, J)\\nImplies(1 trial is open, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(F, J)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(N, J)\\nImplies(3 trials are open, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(F), G)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(L, G)\\nImplies(1 trial is open, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(F, G)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), L)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), 1 trial is open)\\n--------\\nImplies(Not(F), Not(L))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(1 trial is open))\\n--------\\nImplies(Not(G), I)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), 0 trials are closed)\\n--------\\nImplies(N, G)\\nImplies(3 trials are open, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(J, F)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), Not(I))\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), Not(0 trials are closed))\\n--------\\nImplies(B, D)\\nImplies(expected efficacy against tumours with mutations in the HER2 kinase domain, may overcome treatment resistance)\\n--------\\nImplies(B, G)\\nImplies(expected efficacy against tumours with mutations in the HER2 kinase domain, 4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion)\\n--------\\nImplies(Not(G), H)\\nImplies(Not(4 clinical trials for breast carcinoma with ERBB2 V777L as an inclusion criterion), 4 trials are open)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* We have the logical proposition that Lapatinib and neratinib bind to the HER2 kinase domain and are expected to have efficacy against tumors with mutations in the kinase domain. *)\\n(* There is a logical relation Implies(A and B, C), Implies(expected efficacy against tumors with mutations in the kinase domain, an irreversible inhibitor targeted to the HER2 kinase domain) *)\\n(* We can infer that Lapatinib and neratinib are effective in breast cancer patients. *)\\nthen have \"Effective e\" sledgehammer', 'solving time': 104.23491978645325, 'proof tactics': [], 'code': 'theory clinical_102_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Efficacy :: \"event \u21d2 bool\"\\n  Against :: \"event \u21d2 entity \u21d2 bool\"\\n  TumorsWithMutations :: \"entity \u21d2 entity \u21d2 bool\"\\n  \\n  IrreversibleInhibitor :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"event \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  InPatients :: \"event \u21d2 entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  \\n  InclusionCriterion :: \"event \u21d2 bool\"\\n  ForClinicalTrials :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  ClinicalTrials :: \"event \u21d2 nat \u21d2 bool\"\\n  Open :: \"event \u21d2 nat \u21d2 bool\"\\n  Closed :: \"event \u21d2 nat \u21d2 bool\"\\n  \\n  Contain :: \"event \u21d2 bool\"\\n  Trials :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Phase1Phase2 :: \"event \u21d2 nat \u21d2 bool\"\\n  Phase2 :: \"event \u21d2 nat \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Bind e \u2227 To e x z \u2227 To e y z \u2227 Efficacy e \u2227 Against e z\"\\n\\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. IrreversibleInhibitor x \u2227 TargetedTo e \u2227 To e x z \u2227 Overcome e \u2227 TreatmentResistance e \u2227 Effective e \u2227 InPatients e y \u2227 BreastCancerPatients y\"\\n\\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. InclusionCriterion e \u2227 ForClinicalTrials e x y \u2227 ClinicalTrials e 4 \u2227 Open e 4 \u2227 Closed e 0\"\\n\\n(* Explanation 4: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. Contain e \u2227 Trials e x y \u2227 Phase1Phase2 e 1 \u2227 Open e 1 \u2227 Phase2 e 3 \u2227 Open e 3\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x e1 e2 e3. Patient x \u2227 (Benefit e1 \u2227 WithTreatment e1 x Neratinib) \u2228 (Benefit e2 \u2227 WithTreatment e2 x Lapatinib) \u2228 (Access e3 \u2227 ClinicalTrial e3 \u2227 ForTreatment e3 x y)\"\\nproof -\\n  (* From the premise, we know that the patient x exists. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* We have the logical proposition that Lapatinib and neratinib bind to the HER2 kinase domain and are expected to have efficacy against tumors with mutations in the kinase domain. *)\\n  (* There is a logical relation Implies(A and B, C), Implies(expected efficacy against tumors with mutations in the kinase domain, an irreversible inhibitor targeted to the HER2 kinase domain) *)\\n  (* We can infer that Lapatinib and neratinib are effective in breast cancer patients. *)\\n  then have \"Effective e\" <ATP>\\n  (* We also have the logical proposition that ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma. *)\\n  (* There is a logical relation Equivalent(F, J), Equivalent(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria) *)\\n  (* We can conclude that trials contain ERBB2 V777L and breast carcinoma as inclusion criteria. *)\\n  then have \"Trials e x y\" <ATP>\\n  (* Since the patient can benefit from treatment with Neratinib or Lapatinib, we can derive the final conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain\\nB: expected efficacy against tumors with mutations in the kinase domain\\nC: an irreversible inhibitor targeted to the HER2 kinase domain\\nD: may overcome treatment resistance\\nE: effective in breast cancer patients\\nF: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma\\nG: 4 clinical trials for breast carcinoma\\nH: 4 trials are open\\nI: 0 trials are closed\\nJ: trials contain ERBB2 V777L and breast carcinoma as inclusion criteria\\nK: 1 trial is phase 1/phase 2\\nL: 1 trial is open\\nM: 3 trials are phase 2\\nN: 3 trials are open\\n\\nLogical Relations:\\nImplies(A and B, C)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(C, D and E)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, effective in breast cancer patients)\\n--------\\nEquivalent(F, J)\\nEquivalent(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nEquivalent(G, 4)\\n4 clinical trials for breast carcinoma\\n--------\\nEquivalent(H, 4)\\n4 trials are open\\n--------\\nEquivalent(I, 0)\\nNot(0 trials are closed)\\n--------\\nImplies(J, K or M)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 trial is phase 1/phase 2)\\n--------\\nImplies(K and L, 1 and L)\\nTrue\\n--------\\nImplies(M, 3 and N)\\nImplies(3 trials are phase 2, 3 trials are open)\\n--------\\n\\nDerived Implications:\\nImplies(Not(M), G)\\nImplies(Not(3 trials are phase 2), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), F)\\nImplies(Not(4 clinical trials for breast carcinoma), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(E, Not(I))\\nImplies(effective in breast cancer patients, Not(0 trials are closed))\\n--------\\nImplies(F, Not(I))\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Not(0 trials are closed))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 4 trials are open)\\n--------\\nImplies(K, G)\\nImplies(1 trial is phase 1/phase 2, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(N, H)\\nImplies(3 trials are open, 4 trials are open)\\n--------\\nImplies(B, Not(I))\\nImplies(expected efficacy against tumors with mutations in the kinase domain, Not(0 trials are closed))\\n--------\\nImplies(M, H)\\nImplies(3 trials are phase 2, 4 trials are open)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(4 trials are open), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), B)\\nImplies(Not(4 clinical trials for breast carcinoma), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(Not(H), C)\\nImplies(Not(4 trials are open), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(H), M)\\nImplies(Not(4 trials are open), 3 trials are phase 2)\\n--------\\nImplies(Not(K), G)\\nImplies(Not(1 trial is phase 1/phase 2), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(4 trials are open), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(G), C)\\nImplies(Not(4 clinical trials for breast carcinoma), an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(G), M)\\nImplies(Not(4 clinical trials for breast carcinoma), 3 trials are phase 2)\\n--------\\nImplies(H, Not(I))\\nImplies(4 trials are open, Not(0 trials are closed))\\n--------\\nImplies(Not(H), Not(M))\\nImplies(Not(4 trials are open), Not(3 trials are phase 2))\\n--------\\nImplies(Not(H), K)\\nImplies(Not(4 trials are open), 1 trial is phase 1/phase 2)\\n--------\\nImplies(Not(N), H)\\nImplies(Not(3 trials are open), 4 trials are open)\\n--------\\nImplies(Not(K), Not(F))\\nImplies(Not(1 trial is phase 1/phase 2), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), 4 trials are open)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(4 trials are open), effective in breast cancer patients)\\n--------\\nImplies(Not(G), Not(H))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(4 trials are open))\\n--------\\nImplies(I, Not(B))\\nImplies(0 trials are closed, Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(G), Not(M))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(3 trials are phase 2))\\n--------\\nImplies(K, H)\\nImplies(1 trial is phase 1/phase 2, 4 trials are open)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(4 clinical trials for breast carcinoma), effective in breast cancer patients)\\n--------\\nImplies(Not(G), Not(J))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(I, Not(G))\\nImplies(0 trials are closed, Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(C, H)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 4 trials are open)\\n--------\\nImplies(J, F)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(N, G)\\nImplies(3 trials are open, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(C))\\nImplies(0 trials are closed, Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(G), H)\\nImplies(Not(4 clinical trials for breast carcinoma), 4 trials are open)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(4 trials are open), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(B), Not(I))\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), Not(0 trials are closed))\\n--------\\nImplies(Not(H), Not(N))\\nImplies(Not(4 trials are open), Not(3 trials are open))\\n--------\\nImplies(Not(F), Not(I))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(0 trials are closed))\\n--------\\nImplies(Not(N), G)\\nImplies(Not(3 trials are open), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(H), N)\\nImplies(Not(4 trials are open), 3 trials are open)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(M, Not(I))\\nImplies(3 trials are phase 2, Not(0 trials are closed))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(4 trials are open), trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(I, F)\\nImplies(0 trials are closed, ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(M), Not(I))\\nImplies(Not(3 trials are phase 2), Not(0 trials are closed))\\n--------\\nImplies(C, G)\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(E), G)\\nImplies(Not(effective in breast cancer patients), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, B)\\nImplies(0 trials are closed, expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(K, Not(I))\\nImplies(1 trial is phase 1/phase 2, Not(0 trials are closed))\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(Not(H), Not(I))\\nImplies(Not(4 trials are open), Not(0 trials are closed))\\n--------\\nImplies(Not(C), G)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), K)\\nImplies(Not(4 clinical trials for breast carcinoma), 1 trial is phase 1/phase 2)\\n--------\\nImplies(Not(I), G)\\nImplies(Not(0 trials are closed), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, M)\\nImplies(0 trials are closed, 3 trials are phase 2)\\n--------\\nImplies(I, C)\\nImplies(0 trials are closed, an irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(1 trial is phase 1/phase 2), Not(0 trials are closed))\\n--------\\nImplies(I, Not(J))\\nImplies(0 trials are closed, Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(H), Not(K))\\nImplies(Not(4 trials are open), Not(1 trial is phase 1/phase 2))\\n--------\\nImplies(Not(E), H)\\nImplies(Not(effective in breast cancer patients), 4 trials are open)\\n--------\\nImplies(Not(G), Not(K))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(1 trial is phase 1/phase 2))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(effective in breast cancer patients))\\n--------\\nImplies(Not(C), H)\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), 4 trials are open)\\n--------\\nImplies(Not(I), H)\\nImplies(Not(0 trials are closed), 4 trials are open)\\n--------\\nImplies(F, H)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 4 trials are open)\\n--------\\nImplies(N, Not(I))\\nImplies(3 trials are open, Not(0 trials are closed))\\n--------\\nImplies(Not(H), Not(B))\\nImplies(Not(4 trials are open), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(J, G)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), Not(N))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(3 trials are open))\\n--------\\nImplies(G, H)\\nImplies(4 clinical trials for breast carcinoma, 4 trials are open)\\n--------\\nImplies(Not(G), N)\\nImplies(Not(4 clinical trials for breast carcinoma), 3 trials are open)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(4 clinical trials for breast carcinoma), trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(4 trials are open), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(N), Not(I))\\nImplies(Not(3 trials are open), Not(0 trials are closed))\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria), Not(0 trials are closed))\\n--------\\nImplies(E, G)\\nImplies(effective in breast cancer patients, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(H), I)\\nImplies(Not(4 trials are open), 0 trials are closed)\\n--------\\nImplies(I, G)\\nImplies(0 trials are closed, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(J, H)\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, 4 trials are open)\\n--------\\nImplies(C, Not(I))\\nImplies(an irreversible inhibitor targeted to the HER2 kinase domain, Not(0 trials are closed))\\n--------\\nImplies(F, G)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(G), I)\\nImplies(Not(4 clinical trials for breast carcinoma), 0 trials are closed)\\n--------\\nImplies(Not(G), Not(I))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(0 trials are closed))\\n--------\\nImplies(Not(H), F)\\nImplies(Not(4 trials are open), ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(F))\\nImplies(0 trials are closed, Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(B, G)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, Not(H))\\nImplies(0 trials are closed, Not(4 trials are open))\\n--------\\nImplies(I, K)\\nImplies(0 trials are closed, 1 trial is phase 1/phase 2)\\n--------\\nImplies(Not(E), Not(I))\\nImplies(Not(effective in breast cancer patients), Not(0 trials are closed))\\n--------\\nImplies(I, Not(M))\\nImplies(0 trials are closed, Not(3 trials are phase 2))\\n--------\\nImplies(I, E)\\nImplies(0 trials are closed, effective in breast cancer patients)\\n--------\\nImplies(Not(F), Not(J))\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(F, K)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, 1 trial is phase 1/phase 2)\\n--------\\nImplies(Not(B), H)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 4 trials are open)\\n--------\\nImplies(Not(C), Not(I))\\nImplies(Not(an irreversible inhibitor targeted to the HER2 kinase domain), Not(0 trials are closed))\\n--------\\nImplies(E, H)\\nImplies(effective in breast cancer patients, 4 trials are open)\\n--------\\nImplies(H, G)\\nImplies(4 trials are open, 4 clinical trials for breast carcinoma)\\n--------\\nImplies(I, H)\\nImplies(0 trials are closed, 4 trials are open)\\n--------\\nImplies(B, E)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, effective in breast cancer patients)\\n--------\\nImplies(Not(H), B)\\nImplies(Not(4 trials are open), expected efficacy against tumors with mutations in the kinase domain)\\n--------\\nImplies(G, Not(I))\\nImplies(4 clinical trials for breast carcinoma, Not(0 trials are closed))\\n--------\\nImplies(I, Not(K))\\nImplies(0 trials are closed, Not(1 trial is phase 1/phase 2))\\n--------\\nImplies(B, H)\\nImplies(expected efficacy against tumors with mutations in the kinase domain, 4 trials are open)\\n--------\\nImplies(I, Not(E))\\nImplies(0 trials are closed, Not(effective in breast cancer patients))\\n--------\\nImplies(Not(M), H)\\nImplies(Not(3 trials are phase 2), 4 trials are open)\\n--------\\nImplies(Not(G), Not(B))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(4 trials are open), Not(4 clinical trials for breast carcinoma))\\n--------\\nImplies(I, Not(N))\\nImplies(0 trials are closed, Not(3 trials are open))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(effective in breast cancer patients), Not(expected efficacy against tumors with mutations in the kinase domain))\\n--------\\nImplies(I, N)\\nImplies(0 trials are closed, 3 trials are open)\\n--------\\nImplies(Not(H), Not(J))\\nImplies(Not(4 trials are open), Not(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria))\\n--------\\nImplies(Not(B), G)\\nImplies(Not(expected efficacy against tumors with mutations in the kinase domain), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(J, Not(I))\\nImplies(trials contain ERBB2 V777L and breast carcinoma as inclusion criteria, Not(0 trials are closed))\\n--------\\nImplies(I, J)\\nImplies(0 trials are closed, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(4 clinical trials for breast carcinoma), Not(an irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(F, J)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, trials contain ERBB2 V777L and breast carcinoma as inclusion criteria)\\n--------\\nImplies(Not(F), G)\\nImplies(Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma), 4 clinical trials for breast carcinoma)\\n--------\\nImplies(Not(K), H)\\nImplies(Not(1 trial is phase 1/phase 2), 4 trials are open)\\n--------\\nImplies(M, G)\\nImplies(3 trials are phase 2, 4 clinical trials for breast carcinoma)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Since the patient is not directly related to Lapatinib or Neratinib, we need to consider the implications of effectiveness in breast cancer patients. *)\\n(* There is a logical relation Implies(A, B), Implies(Lapatinib and neratinib being effective against tumors with mutations in the kinase domain, they are effective in breast cancer patients) *)\\n(* We can conclude that the patient may benefit from treatment with Neratinib or Lapatinib. *)\\nthen have \"\u2203y. (Neratinib y \u2228 Lapatinib y) \u2227 BenefitFrom e x y\" sledgehammer', 'solving time': 118.55017495155334, 'proof tactics': [], 'code': 'theory clinical_102_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  TumorsWithMutations :: \"entity \u21d2 bool\"\\n  KinaseDomain :: \"entity \u21d2 bool\"\\n  EffectiveAgainst :: \"entity \u21d2 entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  Efficacy :: \"entity \u21d2 bool\"\\n  LeadsToEffectiveness :: \"entity \u21d2 (entity \u21d2 bool) \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  BenefitFrom :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  AccessClinicalTrial :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOf :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib being effective against tumors with mutations in the kinase domain implies that they are effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z. Lapatinib x \u2227 Neratinib y \u2227 TumorsWithMutations z \u2227 KinaseDomain z \u27f6 EffectiveAgainst x z \u2227 EffectiveAgainst y z \u2227 BreastCancerPatients z\"\\n\\n(* Explanation 2: The efficacy of Lapatinib and neratinib against tumors with mutations in the kinase domain leads to their effectiveness in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. Efficacy x \u2227 Lapatinib y \u2227 Neratinib z \u2227 TumorsWithMutations z \u2227 KinaseDomain z \u27f6 (LeadsToEffectiveness x BreastCancerPatients \u2227 LeadsToEffectiveness y BreastCancerPatients)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment e \u2227 (Neratinib y \u2228 Lapatinib y) \u2227 BenefitFrom e x y \u2228 AccessClinicalTrial e x \u2227 TreatmentOf e y (ERBB2 V777L)\"\\nproof -\\n  (* From the premise, we have information about the patient. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There are two relevant explanatory sentences related to the effectiveness of Lapatinib and Neratinib. *)\\n  (* Explanation 1: Lapatinib and neratinib being effective against tumors with mutations in the kinase domain implies that they are effective in breast cancer patients. *)\\n  (* Explanation 2: The efficacy of Lapatinib and neratinib against tumors with mutations in the kinase domain leads to their effectiveness in breast cancer patients. *)\\n  (* We can infer that Lapatinib and Neratinib are effective in breast cancer patients. *)\\n  then have \"EffectiveAgainst Lapatinib z \u2227 EffectiveAgainst Neratinib z \u2227 BreastCancerPatients z\" <ATP>\\n  (* Since the patient is not directly related to Lapatinib or Neratinib, we need to consider the implications of effectiveness in breast cancer patients. *)\\n  (* There is a logical relation Implies(A, B), Implies(Lapatinib and neratinib being effective against tumors with mutations in the kinase domain, they are effective in breast cancer patients) *)\\n  (* We can conclude that the patient may benefit from treatment with Neratinib or Lapatinib. *)\\n  then have \"\u2203y. (Neratinib y \u2228 Lapatinib y) \u2227 BenefitFrom e x y\" <ATP>\\n  (* Additionally, the patient may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n  then have \"\u2203e. AccessClinicalTrial e x \u2227 TreatmentOf e y (ERBB2 V777L)\" <ATP>\\n  (* Combining the above two inferences, we obtain the desired conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib being effective against tumors with mutations in the kinase domain\\nB: they are effective in breast cancer patients\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Lapatinib and neratinib being effective against tumors with mutations in the kinase domain, they are effective in breast cancer patients)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.819732427597046, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  AccessingTreatments :: event \\\\<Rightarrow> bool\\nOperand:   x :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_102_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"event \u21d2 bool\"\\n  Neratinib :: \"event \u21d2 bool\"\\n  BreastCancerPatient :: \"entity \u21d2 bool\"\\n  BenefitForPatient :: \"entity \u21d2 event \u21d2 bool\"\\n  TreatmentOptions :: \"event \u21d2 bool\"\\n  InTermsOf :: \"event \u21d2 event \u21d2 bool\"\\n  PositiveOutcome :: \"event \u21d2 bool\"\\n  AccessingTreatments :: \"event \u21d2 bool\"\\n  Suitable :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients implies a potential benefit for the patient in terms of treatment options. *)\\naxiomatization where\\n  explanation_1: \"\u2200e x y. Lapatinib e \u2227 Neratinib e \u2227 BreastCancerPatient x \u27f6 (BenefitForPatient x e \u2227 TreatmentOptions y \u2227 InTermsOf e y)\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients can lead to a positive outcome for the patient in terms of accessing suitable treatments. *)\\naxiomatization where\\n  explanation_2: \"\u2200e x y z. Lapatinib e \u2227 Neratinib e \u2227 BreastCancerPatient x \u27f6 (PositiveOutcome y \u2227 AccessingTreatments z \u2227 Suitable z \u2227 InTermsOf e z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x y z e. BreastCancerPatient x \u2227 TreatmentOptions e \u2227 (Neratinib e \u2228 Lapatinib e) \u2227 ClinicalTrial z \u2227 ForTreatmentOf e ERBB2 V777L \u2227 BenefitForPatient x e \u2228 AccessingTreatments x z\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatient x\" <ATP>\\n  (* There are two relevant explanatory sentences: Explanation 1 and Explanation 2. *)\\n  (* Explanation 1 states the implication between the effectiveness of Lapatinib and Neratinib and the potential benefit for the patient in terms of treatment options. *)\\n  (* Explanation 2 states the implication between the effectiveness of Lapatinib and Neratinib and the positive outcome for the patient in terms of accessing suitable treatments. *)\\n  (* Both explanations involve Lapatinib, Neratinib, and BreastCancerPatient. *)\\n  (* We can infer that the patient may benefit from treatment options and access suitable treatments. *)\\n  then have \"TreatmentOptions e \u2227 (Neratinib e \u2228 Lapatinib e) \u2227 BenefitForPatient x e \u2228 AccessingTreatments x z\" for e z <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefit for the patient in terms of treatment options\\nC: positive outcome for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefit for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcome for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* The hypothesis involves the potential benefit and positive outcome related to Lapatinib and Neratinib in breast cancer patients. *)\\n(* There are logical relations Implies(A, B) and Implies(A, C) *)\\n(* We can use the known information about BreastCancerPatient x and the logical relations to infer the hypothesis. *)\\n(* Since BreastCancerPatient x is related to the effectiveness of Lapatinib and Neratinib, we can infer the hypothesis. *)\\nthen have \"\u2203x y z e1 e2 e3. Patient x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 With e1 y) \u2228 (Benefit e2 \u2227 Agent e2 x \u2227 With e2 z) \u2228 (Access e3 \u2227 Agent e3 x \u2227 ClinicalTrialFor e3 z))\" sledgehammer', 'solving time': 103.41330003738403, 'proof tactics': [], 'code': 'theory clinical_102_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  BreastCancerPatient :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Potential :: \"event \u21d2 bool\"\\n  TreatmentOptionsFor :: \"event \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  PositiveOutcome :: \"event \u21d2 bool\"\\n  AccessingSuitableTreatmentsFor :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients implies a potential benefit for the patient in terms of treatment options *)\\naxiomatization where\\n  explanation_1: \"\u2200e x y z. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (Benefit e \u2227 Agent e z \u2227 Potential e \u2227 TreatmentOptionsFor e z)\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients can lead to a positive outcome for the patient in terms of accessing suitable treatments *)\\naxiomatization where\\n  explanation_2: \"\u2200e x y z. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (Lead e \u2227 Agent e z \u2227 PositiveOutcome e \u2227 AccessingSuitableTreatmentsFor e z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatient x\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 With e1 y) \u2228 (Benefit e2 \u2227 Agent e2 x \u2227 With e2 z) \u2228 (Access e3 \u2227 Agent e3 x \u2227 ClinicalTrialFor e3 z))\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatient x\" <ATP>\\n  (* The hypothesis involves the potential benefit and positive outcome related to Lapatinib and Neratinib in breast cancer patients. *)\\n  (* There are logical relations Implies(A, B) and Implies(A, C) *)\\n  (* We can use the known information about BreastCancerPatient x and the logical relations to infer the hypothesis. *)\\n  (* Since BreastCancerPatient x is related to the effectiveness of Lapatinib and Neratinib, we can infer the hypothesis. *)\\n  then have \"\u2203x y z e1 e2 e3. Patient x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 With e1 y) \u2228 (Benefit e2 \u2227 Agent e2 x \u2227 With e2 z) \u2228 (Access e3 \u2227 Agent e3 x \u2227 ClinicalTrialFor e3 z))\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefit for the patient in terms of treatment options\\nC: positive outcome for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefit for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcome for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.56659483909607, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   Patient x :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_102_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOptionsFor :: \"event \u21d2 entity \u21d2 bool\"\\n  PositiveOutcomes :: \"event \u21d2 bool\"\\n  AccessingTreatmentsFor :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatients z \u27f6 (Benefit e \u2227 Patient e z \u2227 TreatmentOptionsFor e z)\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatients z \u27f6 (PositiveOutcomes e \u2227 Patient e z \u2227 AccessingTreatmentsFor e z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatients x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 TreatmentOptionsFor e1 x \u2227 Benefit e1 \u2227 Patient e1 x \u2227 TreatmentWith e1 y \u2228 PositiveOutcomes e2 \u2227 Patient e2 x \u2227 AccessingTreatmentsFor e2 z \u2228 AccessingTreatmentsFor e3 x \u2227 ClinicalTrialFor e3 z \u2227 ERBB2V777L z\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatients x\" <ATP>\\n  (* We have the logical propositions A, B, and C from the explanations. *)\\n  (* There are logical relations Implies(A, B) and Implies(A, C). *)\\n  (* We can use these relations to infer the hypothesis. *)\\n  (* Since the patient is a breast cancer patient, we can infer the potential benefits for the patient in terms of treatment options and positive outcomes for the patient in terms of accessing suitable treatments. *)\\n  then have \"\u2203x y z e1 e2 e3. Patient x \u2227 TreatmentOptionsFor e1 x \u2227 Benefit e1 \u2227 Patient e1 x \u2227 TreatmentWith e1 y \u2228 PositiveOutcomes e2 \u2227 Patient e2 x \u2227 AccessingTreatmentsFor e2 z \u2228 AccessingTreatmentsFor e3 x \u2227 ClinicalTrialFor e3 z \u2227 ERBB2V777L z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefits for the patient in terms of treatment options\\nC: positive outcomes for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefits for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcomes for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.474159955978394, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   Patient x :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_102_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  BreastCancerPatient :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"event \u21d2 bool\"\\n  InTermsOf :: \"event \u21d2 entity \u21d2 bool\"\\n  PositiveOutcome :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  SuitableTreatment :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (Benefit e \u2227 Agent e z \u2227 Patient e x) \u2228 (Benefit e \u2227 Agent e z \u2227 Patient e y) \u2228 (TreatmentOption e \u2227 InTermsOf e z)\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (PositiveOutcome e \u2227 Agent e z \u2227 Patient e z) \u2228 (Access e \u2227 Agent e z \u2227 SuitableTreatment e \u2227 InTermsOf e z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 TreatmentOption y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z) \u2228 (Able e3 \u2227 Agent e3 x \u2227 Access e3 z))\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatient x\" <ATP>\\n  \\n  (* We have the logical relations Implies(A, B) and Implies(A, C) *)\\n  (* We can use Explanation 1 and Explanation 2 to infer the hypothesis. *)\\n  \\n  (* From Explanation 1, we can infer the following possibilities: *)\\n  (* 1. Benefit event for the patient x with Lapatinib *)\\n  (* 2. Benefit event for the patient x with Neratinib *)\\n  (* 3. TreatmentOption event in terms of breast cancer for the patient x *)\\n  then have \"\u2203y e1. Patient x \u2227 (Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2228 (TreatmentOption e1 \u2227 InTermsOf e1 x)\" <ATP>\\n  \\n  (* From Explanation 2, we can infer the following possibilities: *)\\n  (* 1. PositiveOutcome event for the patient x with Lapatinib *)\\n  (* 2. Access event for the patient x with suitable treatment in terms of breast cancer *)\\n  then have \"\u2203z e2. Patient x \u2227 (PositiveOutcome e2 \u2227 Agent e2 x \u2227 Patient e2 x) \u2228 (Access e2 \u2227 Agent e2 x \u2227 SuitableTreatment e2 \u2227 InTermsOf e2 x)\" <ATP>\\n  \\n  (* Combining the inferences from Explanation 1 and Explanation 2, we can derive the final hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefits for the patient in terms of treatment options\\nC: positive outcomes for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefits for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcomes for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.689161539077759, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   Patient x :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_102_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  BreastCancerPatient :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"event \u21d2 bool\"\\n  ForPatient :: \"event \u21d2 entity \u21d2 bool\"\\n  PositiveOutcome :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  SuitableTreatment :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (Benefit e \u2227 Agent e z \u2227 Patient e x) \u2228 (Benefit e \u2227 Agent e z \u2227 Patient e y) \u2228 (TreatmentOption e \u2227 ForPatient e z)\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatient z \u27f6 (PositiveOutcome e \u2227 Agent e z \u2227 Patient e z) \u2228 (Access e \u2227 Agent e z \u2227 SuitableTreatment e)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatient x\"\\n  (* Hypothesis: Patients may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for the treatment of ERBB2 V777L. *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 TreatmentOption y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z) \u2228 (Able e3 \u2227 Agent e3 x \u2227 Access e3 z))\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatient x\" <ATP>\\n  (* The hypothesis involves the effectiveness of Lapatinib and Neratinib in breast cancer patients, which relates to logical propositions A, B, and C. *)\\n  (* There are logical relations Implies(A, B) and Implies(A, C). *)\\n  (* We can use these relations to infer the necessary components for the hypothesis. *)\\n  (* Since the patient is a breast cancer patient, we can infer the effects of Lapatinib and Neratinib on the patient. *)\\n  (* This leads to potential benefits for the patient in terms of treatment options and positive outcomes for the patient in terms of accessing suitable treatments. *)\\n  (* Therefore, we can conclude the existence of the required elements in the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefits for the patient in terms of treatment options\\nC: positive outcomes for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefits for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcomes for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* We can then construct the required hypothesis using the inferred information. *)\\nthen show ?thesis sledgehammer', 'solving time': 118.76462483406067, 'proof tactics': [], 'code': 'theory clinical_102_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  PotentialBenefits :: \"entity \u21d2 bool\"\\n  PotentialBenefitsForPatient :: \"entity \u21d2 bool\"\\n  TreatmentOptions :: \"entity \u21d2 bool\"\\n  ResultsIn :: \"event \u21d2 bool\"\\n  PositiveOutcomes :: \"event \u21d2 bool\"\\n  PositiveOutcomesForPatient :: \"entity \u21d2 bool\"\\n  AccessingSuitableTreatments :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to potential benefits for the patient in terms of treatment options *)\\naxiomatization where\\n  explanation_1: \"\u2200e x y z. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatients z \u2227 Effectiveness e \u2227 LeadsTo e \u2227 PotentialBenefits x \u2227 PotentialBenefits y \u2227 PotentialBenefitsForPatient z \u2227 TreatmentOptions z\"\\n\\n(* Explanation 2: The effectiveness of Lapatinib and Neratinib in breast cancer patients results in positive outcomes for the patient in terms of accessing suitable treatments *)\\naxiomatization where\\n  explanation_2: \"\u2200e x y z. Lapatinib x \u2227 Neratinib y \u2227 BreastCancerPatients z \u2227 Effectiveness e \u2227 ResultsIn e \u2227 PositiveOutcomes e \u2227 PositiveOutcomesForPatient z \u2227 AccessingSuitableTreatments z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatients x\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L e1 \u2227 Benefit e2 \u2227 BenefitFrom e2 x y \u2227 BenefitFrom e2 x z \u2227 Access e3 \u2227 AbleTo e3 x \u2227 AccessTo e3 x z\"\\nproof -\\n  (* From the premise, we know that the patient is a breast cancer patient. *)\\n  from asm have \"BreastCancerPatients x\" <ATP>\\n  (* We have the logical propositions A, B, and C related to the effectiveness of Lapatinib and Neratinib. *)\\n  (* There are logical relations Implies(A, B) and Implies(A, C). *)\\n  (* We can use these relations to infer the positive outcomes for the patient in terms of accessing suitable treatments. *)\\n  from explanation_2 and `BreastCancerPatients x` have \"\u2203y z e3. PositiveOutcomesForPatient x \u2227 AccessingSuitableTreatments z\" <ATP>\\n  (* We can then construct the required hypothesis using the inferred information. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: potential benefits for the patient in terms of treatment options\\nC: positive outcomes for the patient in terms of accessing suitable treatments\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, potential benefits for the patient in terms of treatment options)\\n--------\\nImplies(A, C)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, positive outcomes for the patient in terms of accessing suitable treatments)\\n--------\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.181130647659302, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   Patient x :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_102_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  BreastCancerPatient :: \"entity \u21d2 bool\"\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Specific :: \"event \u21d2 bool\"\\n  BenefitFor :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOptions :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  AccessTo :: \"event \u21d2 entity \u21d2 bool\"\\n  ClinicalTrials :: \"event \u21d2 bool\"\\n  SpecificTreatments :: \"event \u21d2 bool\"\\n  ClinicalTrialFor :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOf :: \"event \u21d2 entity \u21d2 bool\"\\n  PositiveOutcomes :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  ResultFrom :: \"event \u21d2 entity \u21d2 bool\"\\n  SuitableTreatments :: \"event \u21d2 bool\"\\n  TailoredTo :: \"event \u21d2 entity \u21d2 bool\"\\n  ConditionOf :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: The effectiveness of Lapatinib and Neratinib in breast cancer patients leads to specific benefits for the patient in terms of treatment options, including the potential to access clinical trials for specific treatments. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e1 e2 e3. BreastCancerPatient x \u2227 Lapatinib y \u2227 Neratinib z \u27f6 (Benefit e1 \u2227 Specific e1 \u2227 BenefitFor e1 x \u2227 TreatmentOptions e2 \u2227 Access e2 \u2227 AccessTo e2 x \u2227 ClinicalTrials e2 \u2227 SpecificTreatments e3 \u2227 ClinicalTrialFor e3 x \u2227 TreatmentOf e3 z)\"\\n\\n(* Explanation 2: The positive outcomes for the patient resulting from the effectiveness of Lapatinib and Neratinib in breast cancer patients include the ability to access suitable treatments tailored to the patient\\'s condition. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e1 e2. BreastCancerPatient x \u2227 Lapatinib y \u2227 Neratinib z \u27f6 (PositiveOutcomes e1 \u2227 Patient e1 x \u2227 ResultFrom e1 y \u2227 ResultFrom e1 z \u2227 Access e2 \u2227 AccessTo e2 x \u2227 SuitableTreatments e2 \u2227 TailoredTo e2 x \u2227 ConditionOf e2 x)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"BreastCancerPatient x\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n shows \"\u2203x y z e1 e2 e3. Patient x \u2227 TreatmentOptions y \u2227 ClinicalTrials z \u2227 ERBB2V777L z \u2227 Benefit e1 \u2227 BenefitFrom e1 x y \u2227 BenefitFrom e1 x z \u2227 Access e2 \u2227 AccessTo e2 x z \u2227 ClinicalTrialFor e2 z \u2227 TreatmentOf e3 z\"\\nproof -\\n  (* From the premise, we know that the patient is a Breast Cancer Patient. *)\\n  from asm have \"BreastCancerPatient x\" <ATP>\\n  (* The hypothesis involves Patient x, TreatmentOptions y, ClinicalTrials z, ERBB2V777L z, Benefit e1, BenefitFrom e1 x y, BenefitFrom e1 x z, Access e2, AccessTo e2 x z, ClinicalTrialFor e2 z, and TreatmentOf e3 z. *)\\n  (* We can use Explanation 1 and Explanation 2 to infer the necessary information. *)\\n  (* Explanation 1 states that the effectiveness of Lapatinib and Neratinib leads to specific benefits for the patient, including access to clinical trials for specific treatments. *)\\n  (* Explanation 2 states that the positive outcomes for the patient include the ability to access suitable treatments tailored to the patient\\'s condition. *)\\n  (* Combining these, we can derive the required information for the hypothesis. *)\\n  from explanation_1 and explanation_2 and asm have \"Patient x \u2227 TreatmentOptions y \u2227 ClinicalTrials z \u2227 ERBB2V777L z \u2227 Benefit e1 \u2227 BenefitFor e1 x \u2227 TreatmentOf e3 z\" <ATP>\\n  then have \"BenefitFrom e1 x y \u2227 BenefitFrom e1 x z \u2227 Access e2 \u2227 AccessTo e2 x z \u2227 ClinicalTrialFor e2 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': \"Logical Propositions:\\nA: effectiveness of Lapatinib and Neratinib in breast cancer patients\\nB: specific benefits for the patient in terms of treatment options, including the potential to access clinical trials for specific treatments\\nC: positive outcomes for the patient resulting from the effectiveness of Lapatinib and Neratinib in breast cancer patients\\nD: ability to access suitable treatments tailored to the patient's condition\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(effectiveness of Lapatinib and Neratinib in breast cancer patients, specific benefits for the patient in terms of treatment options, including the potential to access clinical trials for specific treatments)\\n--------\\nImplies(C, D)\\nImplies(positive outcomes for the patient resulting from the effectiveness of Lapatinib and Neratinib in breast cancer patients, ability to access suitable treatments tailored to the patient's condition)\\n--------\\n\\nDerived Implications:\\n\"}"
        ]
    }
}